| Literature DB >> 34215367 |
Andrea Fava1, Soumya Raychaudhuri2, Deepak A Rao3.
Abstract
The Accelerating Medicines Partnership (AMP) SLE Network united resources from academic centers, government, nonprofit, and industry to accelerate discovery in lupus nephritis (LN). The AMP SLE Network developed a set of protocols for high-throughput analyses to systematically study kidney tissue, urine, and blood in LN. This article summarizes approaches and results from phase 1 of AMP SLE Network effort, including single cell RNA-seq analysis of LN kidney biopsies, cellular and proteomic studies of LN urine, and mass cytometry immunophenotyping of blood cells. This work provides a framework to guide studies of the clinical implications of active cellular/molecular pathways in LN.Entities:
Keywords: AMP; Accelerating medicines partnership; Biomarker; Lupus nephritis; Proteomics; SLE; Transcriptomics; scRNA-seq
Mesh：
Substances：
Year: 2021 PMID： 34215367 DOI： 10.1016/j.rdc.2021.04.003
Source DB: PubMed Journal: Rheum Dis Clin North Am ISSN： 0889-857X Impact factor: 2.670